Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
204.24
+1.69 (0.83%)
At close: Mar 3, 2026, 4:00 PM EST
204.23
-0.01 (0.00%)
Pre-market: Mar 4, 2026, 4:25 AM EST
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $245.17, which forecasts a 20.04% increase in the stock price over the next year. The lowest target is $220 and the highest is $277.
Price Target: $245.17 (+20.04%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $275 → $277 | Buy | Maintains | $275 → $277 | +35.62% | Feb 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $231 → $239 | Strong Buy | Maintains | $231 → $239 | +17.02% | Feb 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $234 → $235 | Buy | Maintains | $234 → $235 | +15.06% | Dec 10, 2025 |
| Stifel | Stifel | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +12.61% | Dec 10, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $270 | Strong Buy | Initiates | $270 | +32.20% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
270.06M
from 268.09M
Increased by 0.74%
Revenue Next Year
321.47M
from 270.06M
Increased by 19.04%
EPS This Year
8.49
from 6.13
Increased by 38.52%
EPS Next Year
9.81
from 8.49
Increased by 15.56%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 291.9M | 360.5M | |||
| Avg | 270.1M | 321.5M | |||
| Low | 248.2M | 288.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.9% | 33.5% | |||
| Avg | 0.7% | 19.0% | |||
| Low | -7.4% | 6.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 9.19 | 10.70 | |||
| Avg | 8.49 | 9.81 | |||
| Low | 7.29 | 8.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 49.9% | 26.0% | |||
| Avg | 38.5% | 15.6% | |||
| Low | 18.9% | 4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.